Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00200343 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 2 versions Re-verified since Mar 7, 2012, no change to tracked fieldsv3-v4
  2. Phase: Not applicable to Phase 3 Results first posted: Nov 7, 2011 · Primary endpoints: 1 to 2 · Enrollment target: 600 to 596 · 4 morev2 Show 7 more changesShow less
    • Results first posted: Nov 7, 2011
    • Primary endpoints: 1 to 2
    • Enrollment target: 600 to 596
    • Interventions: Ursodeoxycholic acid (Drug) to Ursodeoxycholic acid 150mg / day (Drug), Ursodeoxycholic acid 600mg / day (Drug), Ursodeoxycholic acid 900mg / day (Drug)
    • Secondary endpoints: 1 to 4
    • Publications: details revised at 1 of 1 entry
    • Study arms: 0 to 3

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a 24-week multicenter, randomized, double-blind control trial with ursodeoxycholic acid (UDCA) in patients with chronic hepatitis C in Japan. The primary objectives of this study are to verify the superiority of efficacy of UDCA 600 or 900mg/day to that of 150mg/day and the safety of UDCA treatment.
Trial Details
NCT Number NCT00200343
Lead Sponsor Tanabe Pharma Corporation
Conditions Chronic Hepatitis C
Enrollment 596 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov